ClinicalTrials.gov
ClinicalTrials.gov Menu

AMPLATZER™ LAA Occluder Post Approval Study (PAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02964208
Recruitment Status : Recruiting
First Posted : November 16, 2016
Last Update Posted : August 14, 2018
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical

Brief Summary:
The AMPLATZER LAA Occluder is a transcatheter, self-expanding nitinol device intended for use in preventing thrombus embolization from the LAA. The purpose of this study is to compile real world outcome data on the use of AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF)

Condition or disease Intervention/treatment
Atrial Fibrillation Thromboembolism Stroke Device: AMPLATZER™ LAA Occluder

Detailed Description:
The AMPLATZER LAA Occluder device will be clinically evaluated through this post approval study. This is a non-randomized multicenter study on patients who have undergone a procedure to implant an AMPLATZER LAA Occluder or will undergo an implant of an AMPLATZER LAA Occluder.

Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: AMPLATZER™ LAA Occluder Post Approval Study (PAS)
Study Start Date : October 2016
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : October 2023

Resource links provided by the National Library of Medicine



Intervention Details:
  • Device: AMPLATZER™ LAA Occluder
    The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
    Other Names:
    • AMPLATZER™ Cardiac Plug™
    • AMPLATZER™ Amulet™


Primary Outcome Measures :
  1. The occurrence of one or more adverse events listed in description below [ Time Frame: Implant through 24 months ]
    The occurrence of one or more the composite of stroke (including ischemic or hemorrhagic), systemic embolism, or cardiovascular or unexplained death at 24 months from the time of enrollment

  2. The occurrence of ischemic stroke or systemic embolism as listed in description below. [ Time Frame: Implant through 24 months ]
    The occurrence of ischemic stroke or systemic embolism at 24 months from the time of enrollment

  3. The occurrence of a major adverse event within 7 days [ Time Frame: Implant through 7 days ]
    The occurrence of one of the following events between the time of implant and within 7 days of the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure-related events requiring open cardiac surgery or major endovascular repair


Secondary Outcome Measures :
  1. Comparison of the observed rate of ischemic stroke or systemic embolism at 24months with the CHA2DS2-VASc predicted rate [ Time Frame: Implant through 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The subject population will include participants that are > 18 years old and diagnosed with NVAF.
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Documented history of nonvalvular atrial fibrillation
  • Subject intended to be implanted with an AMPLATZER LAA Occluder device

Exclusion Criteria:

  • Women of childbearing potential who are, or plan to become, pregnant during the time of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02964208


Contacts
Contact: Binh Ngo (818) 493-2060 binh.ngo1@abbott.com
Contact: Louie Cabigao (905) 286-4069 louie.cabigao@abbott.com

Locations
Canada, British Columbia
Royal Columbian Recruiting
New Westminster, British Columbia, Canada, V3L 3W5
Contact: Gus Silverio         
Principal Investigator: Albert Chan, MD         
Vancouver General Hospital Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Contact: Naomi Uchida         
Principal Investigator: Jacqueline Saw, MD         
St. Paul's Hospital Recruiting
Vancouver, British Columbia, Canada, V6Z 2E8
Contact: Elizabeth Grieve         
Principal Investigator: John Webb, MD         
Canada, Ontario
Ottawa Heart Institute Recruiting
Ottawa, Ontario, Canada, K1Y 4W7
Contact: Carol Mitchell         
Principal Investigator: Benjamin Hibbert, MD         
Canada, Quebec
Montreal Heart Institute Recruiting
Montreal, Quebec, Canada, H2L 4M1
Contact: Celine Ferland         
Principal Investigator: Reda Ibrahim, MD         
Hotel Dieu de CHUM Recruiting
Montreal, Quebec, Canada, H2W 1T8
Contact: Catherine Bouchard-Pilote         
Principal Investigator: Jean-Bernard Masson, MD         
Chile
Hospital Clinico San Borja Arriarán Recruiting
Santiago, Chile, 8320000
Contact: Maria Vergara         
Principal Investigator: Daniel Aguirre, MD         
Sponsors and Collaborators
St. Jude Medical

Responsible Party: St. Jude Medical
ClinicalTrials.gov Identifier: NCT02964208     History of Changes
Other Study ID Numbers: SJM-CIP-10122
First Posted: November 16, 2016    Key Record Dates
Last Update Posted: August 14, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by St. Jude Medical:
Atrial Fibrillation
Thromboembolism
Stroke
ACP
Left Atrial Appendage
Cardiac Plug
Amulet
Amplatzer

Additional relevant MeSH terms:
Atrial Fibrillation
Thromboembolism
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases